ClinConnect ClinConnect Logo
Search / Trial NCT03749161

Low-add Multifocal vs. Monofocal IOLs

Launched by PRIM. PROF. DR. OLIVER FINDL, MBA · Nov 20, 2018

Trial Information

Current as of June 12, 2025

Unknown status

Keywords

Cataract Surgery Low Add Intraocular Lens

ClinConnect Summary

Spectacle independence is one of the main aims in modern cataract surgery. Although bilateral monofocal IOL implantation, aiming for emmetropia or low myopia, leads to high levels of patient satisfaction in distance vision, spectacle dependence for intermediate vision, reading and other near vision tasks is the usual result.

There are different techniques to reduce spectacle dependence, the most common one is the use of multifocal IOLs. However, a variable number of patients complain of problems, such as glare or haloes (positive dysphotopsia symptoms). Dysphotopsia symptoms may vary signi...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age-related cataract in both eyes
  • Scheduled for bilateral cataract surgery
  • Motivated to be less spectacle dependant in the distance to intermediate vision range
  • Patients with an expected BCDVA of 0.8 snellen score or better after surgery
  • Patients with the need of an IOL Power in the range of 10 to 30D (biometry performed with the IOL master 700)
  • Age 21 and older
  • Written informed consent prior to recruitment
  • Exclusion Criteria:
  • Pregnancy (pregnancy test will be taken pre-operatively in women of reproductive age)
  • Retinopathia pigmentosa
  • Chronic uveitis
  • Amblyopia
  • Pupil decentration \> 1mm center shift
  • preceded retinal surgery
  • preceded Laser-in-situ-Keratomileusis (LASIK)
  • Any ophthalmic abnormality that could compromise visual function or the measurements

About Prim. Prof. Dr. Oliver Findl, Mba

Prim. Prof. Dr. Oliver Findl, MBA, is a distinguished clinical trial sponsor renowned for his expertise in ophthalmology and a strong commitment to advancing medical research. With a robust academic background and extensive clinical experience, he leads innovative studies aimed at improving patient outcomes and fostering breakthroughs in eye care. Dr. Findl combines his clinical acumen with a strategic approach to trial management, ensuring rigorous adherence to ethical standards and regulatory compliance. His dedication to collaboration and excellence positions him as a trusted partner in the development of transformative therapies.

Locations

Vienna, , Austria

Vienna, , Austria

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials